The Largest Prospective Study of IVUS Use to Date1 (n = 8,582)
- IVUS changed clinical decision making 74% of the time
- IVUS use group reported a significant reduction in MI (38%), ST (53%), MACE (35%), and TLR (20%)
- IVUS use was identified as an independent predictor of lower ST incidence
Results from IVUS and No IVUS Study Arms1
Pooled analysis of four registries (n=1670) with LM investigating the clinical impact of using IVUS during revascularization of patients with LM coronary disease with DES.3
1. Hong SJ, Kim BK, Shin DH, et al. Effect of intravascular ultrasound-guided vs angiography-guided everolimus-eluting stent implantation: the IVUS-XPL randomized clinical trial. JAMA. 2015;314(20):2155-2163.
2. Maehara A. ADAPT-DES IVUS Substudy: Utility of IVUS in Delineating the Mechanism of and Preventing Stent Thrombosis. Cardiovascular Research Foundation/Columbia University Medical Center, NY.
3. Hernandez JM, Alonso JA, Hospital JA, et al. Clinical Impact of Intravascular Ultrasound Guidance in Drug-Eluting Stent Implantation for Unprotected Left Main Coronary Disease. J Am Coll Cardiol Intv. 2014;7:244-254.
* MACE includes cardiac death, target lesion-related MI, and ischemia-driven TLR.